ScreenerHero

ANIX Anixa Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · anixa.com
2.890USD-2.03%Mkt Cap: 102.55M $P/E: —

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a ch…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$58.08BUSDP/E 35.4
ARGX
argenx SE
$48.23BUSDP/E 31.4
RVMD
Revolution Medicines, Inc.
$43.05BUSD
UCB
UCB SA
$41.82BUSDP/E 17.8
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap102.55M USD
Enterprise Value90.03M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-10.93M USD
Revenue/Share—
Last Price2.890 USD
Fiscal Year EndOct 2025
MR QuarterJul 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-9.74
PEG-0.11
EV/EBITDA—
EV/Revenue—
P/S—
P/B7.22
EPS (TTM)-0.33
EPS (Forward)-0.31
52W Range
2.32018% of range5.460
52W High5.460 USD
52W Low2.320 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-72.07%
ROA-67.95%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.17M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-3.64%
Net Debt-13.69M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.01
Current Ratio8.54
Quick Ratio7.95
Book Value/Sh0.42 USD
Cash/Share0.40 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateJun 26, 2015
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)9.750 USD
Upside (mean)+237.4%
Target Range6.000 USD – 14.00 USD
6.000+237.4% to mean14.00
# Analysts4
Ownership
Shares Out.34.76M
Float32.81M
Insiders5.62%
Institutions13.83%
Short Interest
Short Ratio3.1d
Short % Float3.20%
Short % Out.3.03%
Shares Short1.05M
Short (prev mo.)977.97K
Technical
SMA 503.157 (-8.5%)
SMA 2002.999 (-3.6%)
Beta0.48
S&P 52W Chg16.45%
Avg Vol (30d)353.12K
Avg Vol (10d)336.51K
Technical Indicators
RSI (14)49.5
MACD-0.0534
MACD Signal-0.0937
MACD Hist.+0.0403
BB Upper3.012 USD
BB Middle2.825 USD
BB Lower2.639 USD
BB Width13.18%
ATR (14)0.1739 USD
Vol Ratio (20d)0.65x